To include your compound in the COVID-19 Resource Center, submit it here.

Rgenta: enhancing interactions between RNA and RNA-binding proteins

Rgenta’s small molecules act like glue between RNA and RNA-binding proteins

Rgenta launched this month with a $20 million seed round to develop compounds that enhance regulatory RNA-protein interactions. The company is disease-agnostic and using amenability to small molecule intervention to guide target selection.

Co-founder, President and CSO Travis Wager told BioCentury Rgenta Therapeutics’ compounds act like glue between RNA molecules and RNA-binding proteins (RBPs) that control RNA processing. Molecules stabilizing

Read the full 602 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers